Loading clinical trials...

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism | Clinical Trials | Clareo Health

COMPLETED

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

NCT00004354•National Center for Research Resources (NCRR)

View on ClinicalTrials.gov

Summary

OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees. II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors). III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA. IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.

Detailed Description

PROTOCOL OUTLINE: Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.

Eligibility

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•PROTOCOL ENTRY CRITERIA:
•-Disease Characteristics-- Diagnosed glucocorticoid-remediable aldosteronism (GRA) with hypertension Hypokalemia is variably seen Blood pressure variably elevated Elevated level of aldosterone Low level of plasma renin activity

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

June 1, 1999

Last Updated

June 24, 2005

Conditions

Hyperaldosteronism

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

NCT06246357

HyperaldosteronismHypercortisolism+1 more

View study

RECRUITINGNA

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

NCT07027254

Primary AldosteronismSecondary Hypertension+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

Inclusion Criteria

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment

Tissue K+ in Primary Hyperaldosteronism

Determination of Threshold Values of Aldosterone in HPLC-MS/MS, of Renin and of the Aldosterone / Renin Ratio for the Diagnosis of Primary Hyperaldosteronism

Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction